Anjali Chandrakant Shah

Ms. Anjali Chandrakant Shah

ICMR-National Institute of Immunohaematology, Mumbai, India
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2021 in Cureus
Verified
Journal Article
Open access
Anjali Chandrakant ShahAnjali Chandrakant Shah
Anjali Chandrakant Shah
RSReema Shah
Reema Shah
GFGermin Fahim
Germin Fahim
LBLindsay Brust-Sisti
Lindsay Brust-Sisti
The current state of the opioid epidemic has revealed the need of utilizing proper pain management, especially in the postoperative setting where there is overuse of potent analgesics. However, the adequate treatment of pain is necessary to reduce mortality and cost of burden while increasing recovery and improving quality of life. Treatment of pain can be difficult to standardize as the guidelines from the American Pain Society discuss the importance of tailoring treatment options based on a patient’s sensitivities and risk factors. An effective fast-acting analgesic with adequate potency and few adverse events is the key to alleviating acute pain. Oliceridine (Olinvyk®, Trevena Inc., Chesterbrook, USA) is a novel G protein-biased μ-opioid receptor agonist designed to decrease opioid-related adverse events (ORAEs) compared to conventional opioids. This article discusses oliceridine’s novel mechanism of action and current place in therapy. After a literature search on clinicaltrials.gov, three clinical trials were analyzed to understand the safety and efficacy of oliceridine. These trials demonstrated a comparable efficacy to morphine with a decreased risk for serious adverse events. However, further studies need to be conducted to evaluate the true safety impact of oliceridine compared to conventional opioids.

14 September 2021 in Cells Tissues Organs
Verified
Journal Article
Closed access
PDF file
UPUrvi Panwar
Urvi Panwar
KMKanchan Mishra
Kanchan Mishra
PPParizad Patel
Parizad Patel
SBSumit Bharadva
Sumit Bharadva
SVSalil Vaniawala
Salil Vaniawala
KGKanjaksha Ghosh
Kanjaksha Ghosh
The quantity of mesenchymal stem/stromal cells (MSCs) required for a particular therapy demands their subsequent expansion through ex vivo culture. During in vitro multiplication, they undergo replicative senescence which may alter their genetic stability. Therefore, this study was aimed to analyze cellular, molecular, and chromosomal alterations in Wharton’s jelly-derived MSCs (WJ-MSCs) during their in vitro sequential passages, where WJ-MSCs were sequentially passaged up to P14 and cells were evaluated at an interval of P2, P6, P10, and P14. They were examined for their morphology, tumorigenicity, surface markers, stemness markers, DNA damage, chromosomal aberration, and telomere length. We have processed five full-term delivered human umbilical cord samples to obtain WJ-MSCs. Morphological appearance observed at initial stages was small fine spindle-shaped WJ-MSCs which were transformed to flat, long, and broader cells in later passages. The cell proliferation rate was gradually decreased after the 10th passage. WJ-MSCs have expressed stemness markers OCT-4 and NANOG, while they showed high expression of positive surface markers CD90 and CD105 and lower expression of CD34 and CD45. They were non-tumorigenic with slow cellular aging during subsequent passages. There was no chromosomal abnormality up to the 14th passage, while increase in comet score and decrease in telomere length were observed in later passages. Hence, our study suggests that early and middle passaged (less than P10) WJ-MSCs are good candidates for clinical administration for treatment.

4 January 2021 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
Anjali Chandrakant ShahAnjali Chandrakant Shah
Anjali Chandrakant Shah
MGMerin George
Merin George
SDSomprakash Dhangar
Somprakash Dhangar
ARAruna Rajendran
Aruna Rajendran
SMSheila Mohan
Sheila Mohan
BVBabu Rao Vundinti
Babu Rao Vundinti

13 July 2023 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
Anjali Chandrakant ShahAnjali Chandrakant Shah
Anjali Chandrakant Shah
CKChandan Kumar
Chandan Kumar
CSChandrakala Shanmukhaiah
Chandrakala Shanmukhaiah
ARAruna Rajendran
Aruna Rajendran
SMSangeeta Mudaliar
Sangeeta Mudaliar
BVBabu Rao Vundinti
Babu Rao Vundinti

14 September 2026 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
Anjali Chandrakant ShahAnjali Chandrakant Shah
Anjali Chandrakant Shah
AYAnchal Yadav
Anchal Yadav
MGMerin George
Merin George
SDSomprakash Dhangar
Somprakash Dhangar
ARAruna Rajendran
Aruna Rajendran
BVBabu Rao Vundinti
Babu Rao Vundinti

18 January 2022 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
SDSomprakash Dhangar
Somprakash Dhangar
PPPurvi Panchal
Purvi Panchal
JGJagdeeshwar Ghatanatti
Jagdeeshwar Ghatanatti
JSJitendra Suralkar
Jitendra Suralkar
Anjali Chandrakant ShahAnjali Chandrakant Shah
Anjali Chandrakant Shah
BVBabu Rao Vundinti
Babu Rao Vundinti